Faron selected Parexel to run its Phase 2 program for bexmarilimab in higher-risk myelodysplastic syndromes, covering sites in the US, UK, and Europe. The study, described as BEXERA Phase 2b, is slated to start in the second half of 2026 and enroll 90 treatment-naïve patients. Parexel will lead protocol execution, including dose testing across multiple levels, with results expected in 2027. Faron said the trial will incorporate newer endpoint criteria designed to better capture clinically meaningful benefit in a heterogeneous, elderly, and frail patient population. The contract highlights the operational and regulatory complexity in HR-MDS development, especially for studies that include bone marrow assessments and require careful endpoint interpretation.